Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06185764 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
A Phase 1 study of Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT06185764 is a Phase 1 study of Myotonic Dystrophy Type 1 (DM1) that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 44 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06185764, a Phase 1 study of Myotonic Dystrophy Type 1 (DM1), is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-670
Study Locations (20)
Other
- Wesley Research Institute - Auchenflower
- Neuroscience Clinical Trials Unit, Alfred Brain - Melbourne
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Leuven
- Hopital de Chicoutimi - Chicoutimi
- Altasciences Montreal - Montreal
- McGIll University - Montreal
- University of Ottawa - Ottawa
- CHU Research Centre of Quebec - Québec
- Neuromuscular Reference Center Institute of Myology - Paris
- Ludwig Maximilians Universitaet Muenchen - München
- Centro Clinico NeMO - Milan
- Maastricht University Medical Center - Maastricht
California
- Stanford Neuromuscular Research - San Carlos
Florida
- University of Florida Clinical Research Center - Gainesville
Kansas
- University of Kansas Medical Center - Fairway
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University School of Medicine / St. Louis Children's Hospital - St Louis
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06185764
The ClinicalTrials.gov registry entry for NCT06185764 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy Type 1 (DM1) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06185764 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06185764 about?
NCT06185764 is a clinical study titled "A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
What is the current status of trial NCT06185764?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2024-02-20. Estimated completion is 2026-12-22.
What conditions does trial NCT06185764 study?
This clinical trial studies the following conditions: Myotonic Dystrophy Type 1 (DM1).
What interventions are being tested in trial NCT06185764?
The interventions under investigation include: Placebo (DRUG), VX-670 (DRUG).
Who is sponsoring clinical trial NCT06185764?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06185764 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy Type 1 (DM1)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.